Shanghai Junshi Biosciences Announces Closure of H Share Register for 2025 AGM
Shanghai Junshi Biosciences Co., Ltd. (Stock code: 1877) has issued an important announcement regarding the upcoming 2025 Annual General Meeting (AGM), which will have direct implications for shareholders of its H Shares. Investors should take note of the following key details:
Key Points of the Announcement
- Closure of Register: The register of members for H Shares will be closed from Tuesday, 23 June 2026 to Friday, 26 June 2026 (both dates inclusive).
- Transfer Restrictions: During this period, no transfer of H Shares will be registered. This means shareholders cannot change their holdings or transfer shares during these dates.
- Record Date: The record date for determining eligibility to attend and vote at the AGM is Friday, 26 June 2026.
- Deadline for Share Registration: To be eligible to attend and vote at the AGM, all transfers of H Shares (with relevant share certificates and transfer forms) must be lodged with the Company’s H Share registrar, Tricor Investor Services Limited, before 4:30 p.m. on Monday, 22 June 2026.
- AGM Details: The AGM will be held on Friday, 26 June 2026. Shareholders on record by the closure date will be able to participate in key company decisions.
Implications for Shareholders and Potential Price Sensitivity
This announcement is critical for current and potential shareholders:
- Voting Rights: Only those registered as shareholders by the cut-off will be eligible to vote at the AGM. This can be significant for investors wishing to influence company decisions or participate in dividend declarations (if any).
- Transfer Freeze: The temporary freeze on share transfers may affect liquidity and trading volumes, potentially impacting share price in the lead-up to the AGM.
- Corporate Governance: AGMs often involve decisions such as director appointments, dividend approvals, and other strategic moves that can affect company valuation and share prices.
Board Composition
The Board of Directors currently includes:
- Executive Directors: Mr. Xiong Jun (Chairman), Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang, and Dr. Li Xin
- Non-Executive Directors: Dr. Yao Sheng and Mr. Tang Yi
- Independent Non-Executive Directors: Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, and Dr. Yang Jin
Important Actions for Shareholders
- Ensure Share Registration: Shareholders who wish to attend or vote at the AGM must ensure their shares are registered with Tricor Investor Services Limited by the deadline.
- Monitor Company Updates: Future announcements regarding AGM agenda items could provide further price-sensitive information.
Conclusion
This announcement is of high importance to investors, as AGMs are often pivotal events for listed companies. Shareholders should act promptly if they intend to participate in the AGM, and monitor subsequent company disclosures for any resolutions that could affect share value.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial advisors and review official company filings before making any investment decisions.
上海君實生物公佈2025年度股東大會將關閉H股股東名冊
上海君實生物科技股份有限公司（股份代號：1877）發佈了一項重要公告，關於即將舉行的2025年度股東大會（AGM），這對H股股東有直接影響。投資者請注意以下重點：
公告重點
- 股東名冊關閉：H股股東名冊將於2026年6月23日（星期二）至2026年6月26日（星期五）期間關閉（包括首尾兩日）。
- 轉讓限制：在此期間，H股將不能進行轉讓登記，即股東無法轉換或轉讓股份。
- 股東資格記錄日：出席及投票資格的記錄日為2026年6月26日（星期五）。
- 股份登記截止時間：欲出席及投票的股東，必須於2026年6月22日（星期一）下午4:30前，將股份及相關證明文件，提交至君實生物H股股份過戶登記處（卓佳證券登記有限公司）。
- 股東大會詳情：AGM將於2026年6月26日（星期五）舉行。於名冊關閉日登記的股東可參與公司重要決策。
對股東的影響及潛在股價敏感事項
此公告對現有及潛在股東極為重要：
- 投票權：只有於截止日前登記的股東才有資格於AGM投票。這對希望參與公司決策或分紅（如有）的投資者尤其重要。
- 股份轉讓凍結：臨時凍結股份轉讓可能影響流動性及交易量，或對AGM前股價產生影響。
- 公司治理：AGM通常涉及董事任命、分紅批准及其他戰略事項，這些都可能影響公司估值及股價。
董事會組成
現時董事會包括：
- 執行董事：熊俊先生（董事長）、李寧博士、鄒建軍博士、李聰先生、張卓兵先生、王剛博士及李昕博士
- 非執行董事：姚勝博士及唐毅先生
- 獨立非執行董事：張春先生、馮曉源博士、李忠賢先生、魯昆女士及楊晉博士
股東重要行動
- 確認股份登記：有意出席或投票的股東，請於截止日前完成股份登記。
- 留意公司後續公告：未來有關AGM議程的公告可能會帶來更多股價敏感資訊。
總結
此公告對投資者至關重要，因AGM通常是上市公司重大事件。股東應及早行動，並密切關注公司後續披露，尤其是有關可能影響股價的議案。
免責聲明：本文僅供資訊參考，不構成任何投資建議。投資者應諮詢財務顧問，並查閱公司官方文件後再作投資決定。
